Figure 2 | Scientific Reports

Figure 2

From: Opposing effects of acute versus chronic inhibition of p53 on decitabine’s efficacy in myeloid neoplasms

Figure 2

p53DD-transduced MLL-AF9 cells were less sensitive to decitabine. (a) Experimental scheme used in (b–d). Mouse bone marrow (BM) cells were transduced with MLL-AF9 (coexpress GFP) and p53DD (coexpress NGFR), and were cultured in vitro or transplanted into recipient mice. (b,c) Cell Viability Assay using vector or p53DD-transduced MLL-AF9 cells, treated with DS-5272 (b) or decitabine (c) at indicated concentrations for 72 h in triplicate. Data are normalized to vehicle control (0 μM group), and are shown as mean ± s.d. (d) Mouse BM cells were retrovirally transduced with MLL-AF9 (coexpress GFP) together with vector or p53DD (coexpress NGFR), and the cells were transplanted into mice. Frequencies of the NGFR+ (vector/p53DD-transduced) fraction in GFP+ (MLL-AF9-transduced) leukemia cells after transplantation are shown. The frequency of p53DD-transduced cells were increased only in mice treated with decitabine (N = 3 per group).

Back to article page